Related references
Note: Only part of the references are listed.CD155 on HIV-Infected Cells Is Not Modulated by HIV-1 Vpu and Nef but Synergizes with NKG2D Ligands to Trigger NK Cell Lysis of Autologous Primary HIV-Infected Cells
Zachary B. Davis et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2017)
A Novel Toll-Like Receptor 9 Agonist, MGN1703, Enhances HIV-1 Transcription and NK Cell-Mediated Inhibition of HIV-1-Infected Autologous CD4+ T Cells
Rasmus Offersen et al.
JOURNAL OF VIROLOGY (2016)
Lysis of HIV-1-infected autologous CD4+ primary T cells by interferon-alpha-activated NK cells requires NKp46 and NKG2D
Costin Tomescu et al.
AIDS (2015)
Targeting NF-κB Signaling with Protein Kinase C Agonists As an Emerging Strategy for Combating HIV Latency
Guochun Jiang et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2015)
Ex Vivo Bioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4+ T Cells from Aviremic Patients
Adam M. Spivak et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations
Gregory M. Laird et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Expanded Cytotoxic T-cell Lymphocytes Target the Latent HIV Reservoir
Julia A. Sung et al.
JOURNAL OF INFECTIOUS DISEASES (2015)
Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with Panobinostat
Rikke Olesen et al.
JOURNAL OF VIROLOGY (2015)
An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression
Gilles Darcis et al.
PLOS PATHOGENS (2015)
A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and various degrees of hepatic function
Marije Slingerland et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
Upregulation of NKG2D ligands in acute lymphoblastic leukemia and non-Hodgkin lymphoma cells by romidepsin and enhanced in vitro and in vivo natural killer cell cytotoxicity
Prakash Satwani et al.
CYTOTHERAPY (2014)
Natural killer cell responses to dendritic cells infected by the ANRS HIV-1 vaccine candidate, MVAHIV
Jean-Saville Cummings et al.
VACCINE (2014)
Reactivation of latent HIV-1 by new semi-synthetic ingenol esters
Diego Pandelo Jose et al.
VIROLOGY (2014)
Activation of HIV Transcription with Short-Course Vorinostat in HIV-Infected Patients on Suppressive Antiretroviral Therapy
Julian H. Elliott et al.
PLOS PATHOGENS (2014)
Histone Deacetylase Inhibitors Impair the Elimination of HIV-Infected Cells by Cytotoxic T-Lymphocytes
Richard Brad Jones et al.
PLOS PATHOGENS (2014)
Histone Deacetylase Inhibitor Romidepsin Induces HIV Expression in CD4 T Cells from Patients on Suppressive Antiretroviral Therapy at Concentrations Achieved by Clinical Dosing
Datsen George Wei et al.
PLOS PATHOGENS (2014)
Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial
Thomas A. Rasmussen et al.
LANCET HIV (2014)
Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cells
Nathalie Fiegler et al.
BLOOD (2013)
Clinical pharmacology profile of vorinostat, a histone deacetylase inhibitor
Marian Iwamoto et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Reactivation of latent HIV by histone deacetylase inhibitors
Kotaro Shirakawa et al.
TRENDS IN MICROBIOLOGY (2013)
Comparison of HDAC inhibitors in clinical development Effect on HIV production in latently infected cells and T-cell activation
Thomas Aagaard Rasmussen et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2013)
An In-Depth Comparison of Latent HIV-1 Reactivation in Multiple Cell Model Systems and Resting CD4+T Cells from Aviremic Patients
Celsa A. Spina et al.
PLOS PATHOGENS (2013)
Post-Treatment HIV-1 Controllers with a Long-Term Virological Remission after the Interruption of Early Initiated Antiretroviral Therapy ANRS VISCONTI Study
Asier Saez-Cirion et al.
PLOS PATHOGENS (2013)
The histone deacetylase inhibitor, romidepsin, suppresses cellular immune functions of cutaneous T-cell lymphoma patients
Michael J. Kelly-Sell et al.
AMERICAN JOURNAL OF HEMATOLOGY (2012)
Stimulation of HIV-1-Specific Cytolytic T Lymphocytes Facilitates Elimination of Latent Viral Reservoir after Virus Reactivation
Liang Shan et al.
IMMUNITY (2012)
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy
N. M. Archin et al.
NATURE (2012)
Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial
Barton F. Haynes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Targeting natural killer cells and natural killer T cells in cancer
Eric Vivier et al.
NATURE REVIEWS IMMUNOLOGY (2012)
Histone deacetylase inhibitors prevent activation of tumour-reactive NK cells and T cells but do not interfere with their cytolytic effector functions
Mareike Schmudde et al.
CANCER LETTERS (2010)
Population Pharmacokinetics of Romidepsin in Patients with Cutaneous T-Cell Lymphoma and Relapsed Peripheral T-Cell Lymphoma
Sukyung Woo et al.
CLINICAL CANCER RESEARCH (2009)
Long-Term Control of HIV by CCR5 Delta32/Delta32 Stem-Cell Transplantaion
Gero Huetter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Synergistic Activation of HIV-1 Expression by Deacetylase Inhibitors and Prostratin: Implications for Treatment of Latent Infection
Sophie Reuse et al.
PLOS ONE (2009)
HIV-1 Vpr Triggers Natural Killer Cell-Mediated Lysis of Infected Cells through Activation of the ATR-Mediated DNA Damage Response
Jeffrey Ward et al.
PLOS PATHOGENS (2009)
Histone deacetylase inhibitors sensitize tumour cells for cytotoxic effects of natural killer cells
Mareike Schmudde et al.
CANCER LETTERS (2008)
Evolutionary struggles between NK cells and viruses
Lewis L. Lanier
NATURE REVIEWS IMMUNOLOGY (2008)
Histone deacetylase inhibitors suppress natural killer cell cytolytic activity
Henry Ogbomo et al.
FEBS LETTERS (2007)
Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B
S Skov et al.
CANCER RESEARCH (2005)
NK cells in HIV infection: Paradigm for protection or targets for ambush
AS Fauci et al.
NATURE REVIEWS IMMUNOLOGY (2005)
Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D Ligands by the histone deacetylase inhibitor sodium valproate
S Armeanu et al.
CANCER RESEARCH (2005)
Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer
WK Kelly et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Can HIV be cured? Mechanisms of HIV persistence and strategies to combat it
DH Hamer
CURRENT HIV RESEARCH (2004)
CD107a as a functional marker for the identification of natural killer cell activity
G Alter et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2004)
Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression
L Ylisastigui et al.
AIDS (2004)
Dual role of prostratin in inhibition of infection and reactivation of human immunodeficiency virus from latency in primary blood lymphocytes and lymphoid tissue
A Biancotto et al.
JOURNAL OF VIROLOGY (2004)
The impaired NK cell cytolytic function in viremic HIV-1 infection is associated with a reduced surface expression of natural cytotoxicity receptors (NKp46, NKp30 and NKp44)
A De Maria et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2003)
Effects of prostratin on T-cell activation and human immunodeficiency virus latency
YD Korin et al.
JOURNAL OF VIROLOGY (2002)
Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART
J Kulkosky et al.
BLOOD (2001)
Share Paper
